Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Active Moderate to Severe Hidradenitis Suppurativa
NCT05322473Phase 2Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Apr 2022
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 7
01
Overview
A Phase 2 trial of sonelokimab in hidradenitis suppurativa (HS), sponsored by MoonLake Immunotherapeutics. Started Apr 2022; status: completed.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT05322473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05322473.